Back

Propanc Biopharma Announces Plan to Purchase $100 Million in Ethereum

The biopharmaceutical company will acquire the cryptocurrency to enhance its asset allocation and accelerate drug development, citing Ethereum's smart contract capabilities and advantages in asset tokenization.

ETH

Summary

According to an official announcement, biopharmaceutical company Propanc Biopharma plans to purchase $100 million in Ethereum over 12 months. This move aims to enhance its crypto asset allocation and speed up drug development, citing Ethereum's smart contract capabilities and tokenization advantages. The company will hold most of the Ethereum, allocating a portion to fund development and IP acquisitions.

Terms & Concepts
  • Ethereum: A decentralized, open-source blockchain platform that enables the creation and execution of smart contracts and decentralized applications (dApps), with its native cryptocurrency being Ether (ETH).
  • Smart Contract: A self-executing contract with the terms of the agreement directly written into code, which runs on a blockchain network like Ethereum.
  • Asset Tokenization: The process of converting rights to a real-world asset into a digital token on a blockchain, which can be traded or stored.